Chronotype and Premature Ejaculation
NCT04841395 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217
Last updated 2021-04-12
Summary
Chronotype (or circadian preference) has previously been shown to be associated with sexual attitudes and behaviors and is an important factor affecting sexual satisfaction. The fact that some neurobiological variables, which are thought to have a role in ejaculation physiology, are also effective in the processes of sleep and the regulation of circadian rhythm, and evidence supporting the relationship between circadian preferences and sexual desire and sexual behavior; suggests that ejaculation disorders may be related to circadian preference. The aim of the present study was to investigate the relationship between intravaginal ejaculatory latency time (IELT), severity of disease and chronotype in lifelong PE.
Conditions
- Premature Ejaculation
Interventions
- DIAGNOSTIC_TEST
-
Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)
Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
Sponsors & Collaborators
-
Bursa Yuksek Ihtisas Training and Research Hospital
lead OTHER_GOV
Principal Investigators
-
Efe Önen, M.D. · Bursa Yuksek Ihtisas Training and Research Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-06-01
- Primary Completion
- 2019-08-30
- Completion
- 2019-12-30
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males
NCT00372008 ·Status: COMPLETED ·Phase: PHASE2
-
TEAM: Testosterone Supplementation and Exercise in Elderly Men
NCT00112151 ·Status: COMPLETED ·Phase: PHASE2
-
Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males
NCT03541395 ·Status: COMPLETED ·Phase: NA
-
A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI
NCT03994263 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
NCT03518034 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations
NCT00857961 ·Status: COMPLETED ·Phase: PHASE2
-
The Testosterone Trials in Older Men
NCT00799617 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
NCT00114114 ·Status: COMPLETED ·Phase: NA
-
Open-Label Study of ARD-0403 in Testosterone Deficient Men
NCT00448955 ·Status: COMPLETED ·Phase: PHASE3
-
Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone
NCT03484260 ·Status: COMPLETED
-
Pharmacokinetic Study of Testosterone Enanthate
NCT01887418 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
NCT01419236 ·Status: COMPLETED ·Phase: PHASE2
-
Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men
NCT00431197 ·Status: COMPLETED ·Phase: PHASE1
-
Short-term Testosterone Replacement in Testicular Cancer Survivors
NCT03339635 ·Status: COMPLETED ·Phase: PHASE2
-
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17
NCT06312761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome
NCT01585831 ·Status: COMPLETED ·Phase: NA
-
Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism
NCT02728440 ·Status: COMPLETED
-
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
NCT01215292 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
NCT02111434 ·Status: COMPLETED ·Phase: PHASE4
-
Cardiovascular Outcomes of Low Testosterone
NCT02758431 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men.
NCT03281187 ·Status: UNKNOWN ·Phase: PHASE3
-
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study
NCT04831099 ·Status: UNKNOWN ·Phase: PHASE3
-
Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males
NCT01133548 ·Status: COMPLETED ·Phase: PHASE1
-
Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment
NCT02034487 ·Status: COMPLETED
-
Calciotropic Effects After HCG Stimulation Test
NCT03254641 ·Status: COMPLETED